JP2023530500A5 - - Google Patents

Info

Publication number
JP2023530500A5
JP2023530500A5 JP2022578719A JP2022578719A JP2023530500A5 JP 2023530500 A5 JP2023530500 A5 JP 2023530500A5 JP 2022578719 A JP2022578719 A JP 2022578719A JP 2022578719 A JP2022578719 A JP 2022578719A JP 2023530500 A5 JP2023530500 A5 JP 2023530500A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
use according
cbd
caffeine
reduces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530500A (ja
Filing date
Publication date
Priority claimed from GBGB2009321.7A external-priority patent/GB202009321D0/en
Application filed filed Critical
Publication of JP2023530500A publication Critical patent/JP2023530500A/ja
Publication of JP2023530500A5 publication Critical patent/JP2023530500A5/ja
Pending legal-status Critical Current

Links

JP2022578719A 2020-06-18 2021-06-16 てんかんの治療におけるカンナビジオールの使用 Pending JP2023530500A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2009321.7A GB202009321D0 (en) 2020-06-18 2020-06-18 Use of cannabinoids in the treatment of epilepsy
GB2009321.7 2020-06-18
PCT/GB2021/051520 WO2021255446A1 (en) 2020-06-18 2021-06-16 Use of cannabidiol in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
JP2023530500A JP2023530500A (ja) 2023-07-18
JP2023530500A5 true JP2023530500A5 (https=) 2024-06-25

Family

ID=71838306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578719A Pending JP2023530500A (ja) 2020-06-18 2021-06-16 てんかんの治療におけるカンナビジオールの使用

Country Status (11)

Country Link
US (1) US20230225986A1 (https=)
EP (1) EP4167980B1 (https=)
JP (1) JP2023530500A (https=)
KR (1) KR20230026337A (https=)
CN (1) CN115916168A (https=)
AU (1) AU2021291128A1 (https=)
CA (1) CA3181694A1 (https=)
GB (2) GB202009321D0 (https=)
MX (1) MX2022016038A (https=)
TW (1) TW202214217A (https=)
WO (1) WO2021255446A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
AU2024300440A1 (en) * 2023-07-25 2026-03-12 Algorae Pharmaceuticals Ltd Compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015308546A1 (en) * 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US20180360771A1 (en) * 2017-06-14 2018-12-20 Yury Leon Shmerlis Cannabidiol chewing gum
GB2568471B (en) 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CN109985042A (zh) * 2017-12-29 2019-07-09 汉义生物科技(北京)有限公司 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用
US20200172841A1 (en) * 2018-12-04 2020-06-04 Donald F. Wilkes Alcohol-free wine beverage

Similar Documents

Publication Publication Date Title
FI4061344T3 (fi) 6-hydroksikannabidioli käytettäväksi lääkkeenä
JP2023168448A5 (https=)
EP3763361B1 (en) Cannabidivarin (cbdv) for use in the treatment of epilepsy
AU2025287414A1 (en) Combinations of cannabinoids and N-acylethanolamines
JP2023503303A5 (https=)
RU2020119390A (ru) Применение каннабиноидов при лечении приступов, связанных с синдромом леннокса-гасто
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2014533680A5 (https=)
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12014500371A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2023530500A5 (https=)
KR101435163B1 (ko) 항말라세지아제
Fernandes Neuroinflammation and Mitochondrial Dysfunction in the Pathogenesis of Alzheimer? s Disease: Modulation by Coriolus Versicolor (Yun-Zhi) Nutritional Mushroom
US20150196614A1 (en) Compounds extracted from palm oil mill effluent for the treatment of cancer, compositions thereof and methods therewith
Namdar et al. Medical Cannabis for the treatment of inflammation
WO2008152068A3 (en) [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
ATE418540T1 (de) Galloylpeptide
CN106038522A (zh) 大黄酸在制备抗抑郁症药物中的用途
EP3280407B1 (en) Use of isothiocyanate derivatives as modulators of peripheral and neuropathic pain
JP7556350B2 (ja) がん細胞増殖抑制剤及びがん細胞増殖抑制用組成物
WO2006126895A3 (en) Cognitive abilities improving agent
CN113116869B (zh) 一种预防和/或治疗抑郁的组合物
WO2007032009A3 (en) Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis
EP3616518B1 (de) Antimikrobielles mittel enthaltend isothiocyanate